Cytomegalovirus (CMV) CD8 T-Cell Immune Competence, Quantitative Assessment by Flow Cytometry
Human CMV (CMV or HCMV) is a member of the herpesvirus family. CMV infection can occur in all ages. CMV infection is usually transmitted through blood, oropharyngeal secretions (e.g., saliva), urine, cervical and vaginal excretions, breast milk, tears, and feces. CMV infection in healthy or immunocompetent individuals is usually asymptomatic and often controlled in the latent form by the immune system. Immunocompromised individuals, including transplant, cancer and AIDS patients, are at significant risk for reactivation of latent infection and the development of severe CMV-associated disease. In addition, primary CMV infection or reactivation during pregnancy can lead to congenital CMV infection in newborn/neonates, which can result in congenital abnormalities including hepatosplenomegaly, deafness, and mental retardation.
The most common clinical manifestations of disease caused by CMV infection in immunocompromised patients includes transplant organ rejection, fever, hematological abnormalities, retinitis, gastroenteritis, hepatitis, encephalitis, esophagitis, enterocolitis, pancreatitis, and pneumonia. Since CMV infection is an opportunistic infection, monitoring for CMV infection is important in the immunocompromised patient population. CMV viremia (detection of viral particle in blood) is a reliable predictor of disease development and an indicator for treatment. Therefore, CMV DNA quantitation is useful for determining active infection and guiding decisions about preemptive therapy and/or prophylaxis in these patients.
The most common method for evaluation for the presence of CMV is amplification by Polymerase Chain Reaction (PCR) and/or modified PCR method also known as Real-Time PCR. This method is very powerful and can detect very low numbers of viral particles. This method is rapid since it amplifies and detects the target DNA sequences at the same time.
- Differential diagnosis of active or reactivated infection in immunocompromised patients
- Assessment of the need for preemptive or prophylactic anti-CMV specific antiviral treatment in transplant patients
- Management of solid-organ transplant patients who are undergoing anti-CMV therapy
- Monitoring response to CMV-specific antiviral therapy
Not Detected or <200 IU/mL (220 copies/mL), but depends on the technology used
<400 copies/mL would be considered negative in patients with a positive history of CMV infection
Plasma EDTA (lavender top tube)
Stability
- Room temperature: up to 6 hours
- Refrigerated: up to 7 days
- Frozen: up to 6 weeks
Note: Plasma must be separated within 6 hours
- Clin Microbiol Infect. 2005 Jul;11(7):518-30. [PMID: 15966969]
- Ann Intern Med. 2005;143:870. [PMID: 16365468]
- Transfus Med. 1999 Jun;9(2):115-23. [PMID: 10354380]
- Curr Opin Infect Dis. 2007 Aug;20(4):408-11. [PMID: 17609601]
- Knipe D and Howley P. (Eds). Fields Virology: Cytomegalovirus. Lippincott, Williams and Wilkins, Philadelphia. 2001; 2675-2706.